Vecuronium bromide

Research use only, not for human use.

Vecuronium (bromide) is a muscle relaxant in the category of non-depolarizing blocking agents.

Vecuronium (bromide) is a muscle relaxant in the category of non-depolarizing blocking agents.(In Vitro):Vecuronium bromide (0-100 μM, 15 min) inhibits [3H] norepinephrine (NE) uptake to 65% at 100 μM in adrenal medullary cells.Vecuronium bromide (0-15 μM,72 hours) inhibits cancer cell proliferation and migration in a concentration-dependent manner.Vecuronium bromide (0-15 μM,72 hours) can significantly reduce cell viability by combining with cisplatin.(In Vivo):Vecuronium bromide (Intravenous injection, 0-5 μM, every 30 min, 2 hours) attenuates the response of carotid sinus nerve activity (CSNA) to hypoxia in a dose-dependent manner and inhibits the neural response of the carotid body to acetylcholine (ACh) in Wister rats.

Vecuronium bromide (0-100 μM, 15 min) inhibits [3H] norepinephrine (NE) uptake to 65% at 100 μM in adrenal medullary cells.Vecuronium bromide (0-15 μM,72 hours) inhibits cancer cell proliferation and migration in a concentration-dependent manner.Vecuronium bromide (0-15 μM,72 hours) can significantly reduce cell viability by combining with cisplatin.Cell Proliferation Assay Cell Line:Lung cancer cell line (A549)Concentration:0-15 μM Incubation Time:72 hours Result:Inhibited cell proliferation at concentrations ranging from 5.0 μM to 15 μM.Cell Cytotoxicity Assay Cell Line:Lung cancer cell line (A549)Concentration:0-15 μM Incubation Time:72 hours Result:Resulted in a decrease in cell viability from 10 μM to 15 Μm by combining with cisplatin.

Vecuronium bromide (Intravenous injection, 0-5 μM, every 30 min, 2 hours) attenuates the response of carotid sinus nerve activity (CSNA) to hypoxia in a dose-dependent manner and inhibits the neural response of the carotid body to acetylcholine (ACh) in Wister rats. Animal Model:Wister rats weighing 250-350 gDosage:0-5 μM Administration:Intravenous injection; every 30 min; 2 hours Result:Significantly diminished CSNA response to hypoxia at the concentration of 5 μM and reduced carotid sinus nerve response to ACh at 0.5 μM.

NC 45

Endocrinology/Hormones

AChR

nAChR

Neurological Disease

——

50700-72-6

637.73

C34H57BrN2O4

>98% (HPLC)

Ethanol: 100 mg/mL (156.8 mM); Water: 4 mg/mL (6.27 mM); DMSO: 100 mg/mL (156.8 mM)

CC(O[C@@H]1[C@@H](N2CCCCC2)C[C@]3(C)[C@@]4([H])CC[C@]5(C)[C@H](OC(C)=O)[C@@H]([N+]6(C)CCCCC6)C[C@@]5([H])[C@]4([H])CC[C@@]3([H])C1)=O.[Br-]

1-((2S,3S,5S,8R,9S,10S,13S,14S,16S,17S)-3,17-diacetoxy-10,13-dimethyl-2-(piperidin-1-yl)hexadecahydro-1H-cyclopenta[a]phenanthren-16-yl)-1-methylpiperidin-1-ium bromide

(-20℃)

With Ice Pack

≥ 2 years